US Patent 12,582,655: What Claims Actually Cover in Tenosynovial Giant Cell Tumor Treatment and Where the Patent Fence Likely Sits
US Drug Patent 12,582,655 is a method-of-treatment patent directed to tenosynovial giant cell tumor (TGCT) using a pharmaceutical composition containing a specific compound (the claim text you provided shows the compound by a “compound represented by:” placeholder). The independent claim scope is anchored to: (i) daily-to-weekly dosing regimens and (ii) fixed 30 mg twice-weekly dosing in dependent claim sets, with additional claim coverage for localized vs diffuse-type TGCT and for neoadjuvant vs adjuvant use.
What is the core independent claim scope? (Claims 1, 12, and 21)
Claim 1 (broad regimen claim)
A method of treating TGCT by administering a composition comprising:
- the claimed compound (structure/formula placeholder “represented by: …”)
- a pharmaceutically acceptable excipient
with a dosing schedule providing the compound about 2 mg to about 60 mg administered at one of the following frequencies:
- once a day
- twice daily
- every other day
- once a week
- twice weekly
- three times a week
Claim 12 (narrow fixed-dose regimen claim)
Same treatment framework, but dosing is explicitly:
- provide the patient 30 mg of the compound twice weekly
Claim 21 (broad “therapeutically effective amount” claim)
Same treatment framework, but dose is not fixed; it requires:
- a therapeutically effective amount of the compound
(no mg range recited in this claim as provided)
Scope implication
- Claim 1 is the widest dosing-frequency and mg-range combination claim.
- Claim 12 is the most infringement-relevant “bright line” dose claim at 30 mg twice weekly.
- Claim 21 is broader conceptually (therapeutic effective amount) but still tied to the exact compound and the TGCT indication; infringement turns on whether the administered amount qualifies as “therapeutically effective” in practice.
How do dependent claims narrow indication and dosing duration? (Claims 2–11, 13–20, 22–29)
Across the three claim groupings (based on claims 1, 12, and 21), dependent claims follow the same structure:
- TGCT subtype limitation (localized vs diffuse-type)
- dosing duration (about 3 months, 6 months, 1 year, 2 years)
- treatment setting (neoadjuvant vs adjuvant)
TGCT subtype limitations
- Claim 2: localized TGCT (depends from claim 1)
- Claim 3: diffuse-type TGCT (depends from claim 1)
- Claim 13: localized TGCT (depends from claim 12)
- Claim 14: diffuse-type TGCT (depends from claim 12)
- Claim 22: localized TGCT (depends from claim 21)
- Claim 23: diffuse-type TGCT (depends from claim 21)
Dosing duration limitations
For each claim grouping, the patent recites administration twice weekly for set durations:
- about 3 months (Claims 6, 15, 24)
- about 6 months (Claims 7, 16, 25)
- about 1 year (Claims 8, 17, 26)
- about 2 years (Claims 9, 18, 27)
Treatment setting
- Neoadjuvant: Claims 10, 19, 28
- Adjuvant: Claims 11, 20, 29
What the dependent claims mean for infringement risk
The dependent set makes it harder to design around by changing:
- TGCT subtype labeling (localized vs diffuse)
- treatment duration (the patent enumerates common clinical time windows)
- clinical role (neoadjuvant or adjuvant)
A product can still avoid infringement if it avoids the recited combinations (dose, frequency, and timing) and avoids the “compound represented by” requirement. But if the product uses the exact compound and lands inside these parameters, the dependent claims reinforce coverage.
Claim Chart by Parameter: Where the Patent Fences the Commercial Territory
Dose and frequency grid reflected in the claims
| Claim family |
Dose requirement |
Frequency requirement |
Numeric precision level |
| Claim 1 |
~2 mg to ~60 mg |
once daily / twice daily / every other day / once weekly / twice weekly / 3x weekly |
Range plus “about” |
| Claim 12 |
30 mg |
twice weekly |
Fixed dose |
| Claim 21 |
therapeutically effective amount |
implied by dependent time claims in 15–18 and 24–27; otherwise not specified in the independent text you provided |
Qualitative standard |
Duration windows explicitly claimed (all “twice weekly”)
| Duration |
Claims tied to dose-frequency “twice weekly” |
| about 3 months |
6, 15, 24 |
| about 6 months |
7, 16, 25 |
| about 1 year |
8, 17, 26 |
| about 2 years |
9, 18, 27 |
Clinical role constraints
| Clinical role |
Claims |
| Neoadjuvant |
10, 19, 28 |
| Adjuvant |
11, 20, 29 |
Disease subtype constraints
| TGCT subtype |
Claims |
| localized |
2, 13, 22 |
| diffuse-type |
3, 14, 23 |
What is Not in the Claims You Provided (and why it matters for design-around)
Based strictly on the claim text provided (with the compound placeholder unfilled), the claims:
- do not recite administration route, formulation form (tablet vs capsule), or specific excipients beyond “pharmaceutically acceptable excipient”
- do not recite specific biomarkers, patient selection criteria, tumor response endpoints, or imaging thresholds
- do not recite treatment discontinuation rules, dose adjustments, or washout logic
That absence matters because it reduces avenues to argue non-infringement based on changes to route/formulation or monitoring approach, so long as the accused product uses the claimed compound and dosing schedule that matches the claims.
Patent Landscape Read: How This Patent Likely Sits in the TGCT “Compound + Regimen + Indication” Layer
Without bibliographic details (assignee, filing date, expiration, continuation status) and without seeing the “compound represented by” structure or name, a complete US landscape mapping (family members, continuations, related US applications, Orange Book ties, or PTAB posture) cannot be validated from the information supplied. The scope analysis below is limited to the claim mechanics you provided and the practical fence it creates in the TGCT treatment regimen space.
Landscape structure inferred from claim architecture
This patent uses a common and enforceable structure in drug-method portfolios:
- Compound identity: fixed by “compound represented by”
- Indication: TGCT (localized and diffuse-type variants)
- Regimen: dose range/frequency (claim 1), exact dose (claim 12), and “therapeutically effective amount” (claim 21)
- Duration and setting: explicitly claimed time windows (3 months to 2 years, twice weekly) and “neoadjuvant/adjuvant”
That pattern typically overlaps with:
- earlier composition or compound-formula patents (foundation)
- later method/regimen patents (line-extension around dosing, schedules, and clinical roles)
If other TGCT patents exist in the same family, they usually cover:
- specific dosing regimens at particular mg amounts
- patient subset definitions (localized vs diffuse)
- combination therapy vs monotherapy (not present in your claim set)
- formulation or delivery (not present here)
Enforcement leverage points
- Claim 12 (30 mg twice weekly) is the highest leverage because it is specific enough to align with product labels or clinical protocols.
- The duration dependent claims allow argument that a clinician’s regimen “as administered” matches the claims, even if the regimen is not always the exact mg range used in claim 1.
- The localized/diffuse limitations block a simple “it’s the other subtype” escape if the drug is used across both.
Practical Infringement Risk Scenarios Based on the Claim Language
If the accused therapy uses the same compound
- Any regimen that administers 2–60 mg at any of the listed frequencies can implicate Claim 1.
- Any regimen that administers 30 mg twice weekly can implicate Claim 12, even if the mg-range regimen in claim 1 is avoided.
- Any regimen where clinicians administer a dose that qualifies as “therapeutically effective amount” can implicate Claim 21, with dependent duration/setting/subtype claims strengthening the case.
If the accused therapy uses a different compound
None of the claims read on it, because the “compound represented by” element is a gatekeeper limitation.
Key Takeaways
- US 12,582,655 is a TGCT method-of-treatment patent tied to a specific “compound represented by” plus pharmaceutically acceptable excipient.
- Coverage is built around three independent claim anchors:
- Claim 1: ~2–~60 mg with multiple dosing frequencies (including twice weekly and 3x weekly)
- Claim 12: 30 mg twice weekly
- Claim 21: therapeutically effective amount
- Dependent claims add enforceable specificity on localized vs diffuse-type TGCT, twice-weekly treatment duration (about 3 months, 6 months, 1 year, 2 years), and neoadjuvant vs adjuvant use.
- The claim set omits route/formulation/biomarker requirements, which narrows design-around paths when the same compound is used.
- A full US patent landscape (families, continuations, priority, expiration, Orange Book linkage, and related claim sets) cannot be deterministically produced from the information provided; the enforceable “fence” that matters for freedom-to-operate is the compound + TGCT indication + regimen/time/subtype/clinical setting structure reflected in these claims.
FAQs
1) What is the most specific claim in US 12,582,655?
Claim 12 is the most specific because it requires 30 mg administered twice weekly.
2) Do the claims cover both localized and diffuse-type TGCT?
Yes. Localized appears in Claims 2, 13, 22 and diffuse-type appears in Claims 3, 14, 23.
3) What duration windows are explicitly claimed?
For twice-weekly dosing: about 3 months, about 6 months, about 1 year, and about 2 years (Claims 6–9, 15–18, 24–27).
4) Does the patent restrict treatment to adjuvant or neoadjuvant?
It covers both. Neoadjuvant is claimed in Claims 10, 19, 28 and adjuvant in Claims 11, 20, 29.
5) Can design-around be achieved by changing the excipient or formulation?
Not based on these claims. The claims only require a pharmaceutically acceptable excipient and do not specify formulation form or route.
References (APA)
[1] User-provided claim text for “United States Drug Patent 12,582,655” (Claims 1–29 as supplied).
